Maximilian von Eynatten is a board certified nephrologist with additional specialization in diabetes (DDG). Dr. von Eynatten serves as an Associate Professor for Medicine at the Technical University in Munich and currently holds the position of the Global Head of Medical Affairs at Boehringer Ingelheim, Germany.
In this role he is supporting the development of novel treatment options for patients with metabolic conditions, such as type 1 and type 2 diabetes. Dr. von Eynatten has a track record in clinical and experimental research exploring the role of adipokines in cardiometabolic conditions and identifying novel markers for early renal and macrovascular complications in type 2 diabetes. In his current role he is focusing on improving renal and CV outcomes in type 2 diabetes serving as a steering committee member in large clinical outcome trials (e.g. CAROLINA and CARMELINA). More recently he has also focused on renal hemodynamic and vascular effects of SGLT2 inhibitors in diabetes and CKD.